Andriy E. Dorofeyev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andriy E. Dorofeyev has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- S. M. Tkach
Ukrainian Scientific and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
23 shared publications - Nataliya Kharchenko
SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE
9 shared publications - H. A. Dorohavtseva
Feofaniya Clinical Hospital of the State Management of Affairs, Kyiv, Ukraine
7 shared publications Y. Z. Hurkalo
6 shared publicationsЮ. З. Гуркало
Українська військово-медична академія, Київ
6 shared publicationsO. M. Kryvoruk
Клінічна лікарня «Феофанія» ДУС, Київ
3 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 16-21
Association between MMP9 gene polymorphism and diverticular disease of the colon in patients residing in the central region of Ukraine
Objective — to investigate the frequency of the –1562C > T (rs3918242) polymorphic variant of the matrix metalloproteinase-9 (MMP9) gene and to evaluate its association with disease course in patients with different clinical variants of diverticular disease. Materials and methods. The study included 133 patients, residents of the central region of Ukraine, who received inpatient treatment at Feofaniya Clinical Hospital (State Administration of Affairs of Ukraine) from June to December 2024. Among them, 97 patients had colonic diverticula: 27 with diverticulosis and 70 with symptomatic diverticular disease. The control group consisted of 36 individuals without diverticula. All participants underwent colonoscopy to confirm the presence or absence of diverticula. Genotyping of the –1562C > T (rs3918242) polymorphism of the MMP9 gene was performed using peripheral blood samples in both patients with diverticula and control subjects. Results. The genotype frequencies of the –1562C > T (rs3918242) polymorphism of the MMP9 gene in patients with diverticula and controls were as follows: CC — 75.3% vs 69.5% (p=0.49), CT — 23.7% vs 27.7% (p=0.63), and TT — 1.0% vs 2.8% (p=0.47), respectively. The genotype distribution conformed to Hardy–Weinberg equilibrium, and no statistically significant differences between the groups were found (χ2=0.28; p=0.59). The allele frequencies of the MMP9 gene (rs3918242) in patients with diverticula were: C — 87.1% and T — 12.9%; in the control group: C — 83.3% and T — 16.7% (p=0.43). All inheritance models demonstrated no association between the –1562C > T (rs3918242) polymorphism of the MMP9 gene and the development of diverticula. The T allele frequency was 15.7% in patients with symptomatic diverticular disease compared with 5.6% in patients with asymptomatic diverticulosis (p=0.043). Conclusions. The frequency of the –1562C > T (rs3918242) polymorphism of the MMP9 gene did not differ significantly between patients with colonic diverticula and controls, indicating no statistically significant association between this polymorphism of the MMP9 gene and the presence of diverticula. However, the T allele was significantly more frequent in patients with symptomatic diverticular disease compared with those with diverticulosis.
- 22 June 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 16-21
Open AccessAssociation between MMP9 gene polymorphism and diverticular disease of the colon in patients residing in the central region of Ukraine
Objective — to investigate the frequency of the –1562C > T (rs3918242) polymorphic variant of the matrix metalloproteinase-9 (MMP9) gene and to evaluate its association with disease course in patients with different clinical variants of diverticular disease. Materials and methods. The study included 133 patients, residents of the central region of Ukraine, who received inpatient treatment at Feofaniya Clinical Hospital (State Administration of Affairs of Ukraine) from June to December 2024. Among them, 97 patients had colonic diverticula: 27 with diverticulosis and 70 with symptomatic diverticular disease. The control group consisted of 36 individuals without diverticula. All participants underwent colonoscopy to confirm the presence or absence of diverticula. Genotyping of the –1562C > T (rs3918242) polymorphism of the MMP9 gene was performed using peripheral blood samples in both patients with diverticula and control subjects. Results. The genotype frequencies of the –1562C > T (rs3918242) polymorphism of the MMP9 gene in patients with diverticula and controls were as follows: CC — 75.3% vs 69.5% (p=0.49), CT — 23.7% vs 27.7% (p=0.63), and TT — 1.0% vs 2.8% (p=0.47), respectively. The genotype distribution conformed to Hardy–Weinberg equilibrium, and no statistically significant differences between the groups were found (χ2=0.28; p=0.59). The allele frequencies of the MMP9 gene (rs3918242) in patients with diverticula were: C — 87.1% and T — 12.9%; in the control group: C — 83.3% and T — 16.7% (p=0.43). All inheritance models demonstrated no association between the –1562C > T (rs3918242) polymorphism of the MMP9 gene and the development of diverticula. The T allele frequency was 15.7% in patients with symptomatic diverticular disease compared with 5.6% in patients with asymptomatic diverticulosis (p=0.043). Conclusions. The frequency of the –1562C > T (rs3918242) polymorphism of the MMP9 gene did not differ significantly between patients with colonic diverticula and controls, indicating no statistically significant association between this polymorphism of the MMP9 gene and the presence of diverticula. However, the T allele was significantly more frequent in patients with symptomatic diverticular disease compared with those with diverticulosis.
- Open Access
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 21-32
Bile tract and liver injuries in patients with systemic metabolic disorders and treatment possibilities
Objective — to assess the features of the biliary tract and liver damage in patients with systemic metabolic disorders (SMD) and analyze the efficacy of ursodeoxycholic acid in complex therapy. Materials and methods. We monitored 120 patients with SMD (67 (55.8%) women and 53 (44.2%) men aged between 36 and 67). In patients included in the study, more than three diseases characteristic of SMD were detected. All patients were diagnosed with DM‑2 with overweight, or obesity of I — II degree, metabolically associated steatotic liver disease and dyslipidemia. In addition to clinical examination, patients underwent laboratory tests: glucose, glycated hemoglobin (HbA1c), bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma‑glutamyl transpeptidase (GGT) and lipid profile with analysis of total cholesterol, triglycerides (TG), high‑density lipoprotein cholesterol (HDL‑C), low‑density lipoprotein cholesterol (LDL‑C) as well as a complete blood count. Patients underwent multimodal ultrasound (US) with the study of ultrasound attenuation coefficient and stiffness of the liver parenchyma, as well as ultrasound of the biliary tract and gallbladder (GB) and dynamic ultrasound of the GB with a trial breakfast. In order to diagnose small intestinal bacterial overgrowth (SIBO) as a marker of the presence of microbiome disorders, patients underwent an H2‑lactulose breath test. Results. Patients with SMD with lesions of the biliary tract and liver did not have specific clinical symptoms. The dominant complaint was pain and a feeling of heaviness in the right upper quadrant with dyspeptic phenomena and manifestations of asthenovegetative syndrome. These changes were combined with a slight increase in AST and ALT, and an increase in the level of GGT, as well as dyslipidemia with an increase in total cholesterol, triglycerides and LDL‑C with an increase in the atherogenic index. Patients had changes in the intestinal microbiome with the development of SIBO, which may be pathogenetic links in the progression of the disease. In these patients, the main US liver damage criteria were revealed: an increase in its size, homogeneous hyperechogenicity of the parenchyma with the effect of distal echo attenuation, and an indistinct vascular bundle, which was combined with an increase in the ultrasound attenuation coefficient and stiffness of the liver parenchyma, and indicated the progression of steatosis and fibrosis. Patients with a decreased GB contraction function, with a decreased GB emptying coefficient (EC), with an increase in the density and thickness of its wall, and an increase in the density of the bile dominated. The use of Ursoker in complex therapy of such patients accelerated the improvement of the clinical picture, contributed to the normalization of cytolysis markers (AST, ALT and GGT), a reduction in the frequency and intensity of SIBO, and had a pronounced lipid‑lowering effect with a reduction in total cholesterol and triglyceride levels and a tendency towards normalisation of the atherogenic index. The use of Ursoker in complex therapy led to a decrease in the frequency and intensity of SIBO. These patients showed a decrease in hyperechogenicity of the liver parenchyma in combination with a decrease in the ultrasound attenuation coefficient, as well as an increase in the GB EC, a decrease in the thickness and density of the GB wall and bile, which can prevent further progression of biliary tract damage in patients with SMD. Conclusions. The use of Ursoker is effective and safe in the complex therapy of SMD patients with hepatobiliary system lesions.
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 21-32
Open AccessBile tract and liver injuries in patients with systemic metabolic disorders and treatment possibilities
Objective — to assess the features of the biliary tract and liver damage in patients with systemic metabolic disorders (SMD) and analyze the efficacy of ursodeoxycholic acid in complex therapy. Materials and methods. We monitored 120 patients with SMD (67 (55.8%) women and 53 (44.2%) men aged between 36 and 67). In patients included in the study, more than three diseases characteristic of SMD were detected. All patients were diagnosed with DM‑2 with overweight, or obesity of I — II degree, metabolically associated steatotic liver disease and dyslipidemia. In addition to clinical examination, patients underwent laboratory tests: glucose, glycated hemoglobin (HbA1c), bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma‑glutamyl transpeptidase (GGT) and lipid profile with analysis of total cholesterol, triglycerides (TG), high‑density lipoprotein cholesterol (HDL‑C), low‑density lipoprotein cholesterol (LDL‑C) as well as a complete blood count. Patients underwent multimodal ultrasound (US) with the study of ultrasound attenuation coefficient and stiffness of the liver parenchyma, as well as ultrasound of the biliary tract and gallbladder (GB) and dynamic ultrasound of the GB with a trial breakfast. In order to diagnose small intestinal bacterial overgrowth (SIBO) as a marker of the presence of microbiome disorders, patients underwent an H2‑lactulose breath test. Results. Patients with SMD with lesions of the biliary tract and liver did not have specific clinical symptoms. The dominant complaint was pain and a feeling of heaviness in the right upper quadrant with dyspeptic phenomena and manifestations of asthenovegetative syndrome. These changes were combined with a slight increase in AST and ALT, and an increase in the level of GGT, as well as dyslipidemia with an increase in total cholesterol, triglycerides and LDL‑C with an increase in the atherogenic index. Patients had changes in the intestinal microbiome with the development of SIBO, which may be pathogenetic links in the progression of the disease. In these patients, the main US liver damage criteria were revealed: an increase in its size, homogeneous hyperechogenicity of the parenchyma with the effect of distal echo attenuation, and an indistinct vascular bundle, which was combined with an increase in the ultrasound attenuation coefficient and stiffness of the liver parenchyma, and indicated the progression of steatosis and fibrosis. Patients with a decreased GB contraction function, with a decreased GB emptying coefficient (EC), with an increase in the density and thickness of its wall, and an increase in the density of the bile dominated. The use of Ursoker in complex therapy of such patients accelerated the improvement of the clinical picture, contributed to the normalization of cytolysis markers (AST, ALT and GGT), a reduction in the frequency and intensity of SIBO, and had a pronounced lipid‑lowering effect with a reduction in total cholesterol and triglyceride levels and a tendency towards normalisation of the atherogenic index. The use of Ursoker in complex therapy led to a decrease in the frequency and intensity of SIBO. These patients showed a decrease in hyperechogenicity of the liver parenchyma in combination with a decrease in the ultrasound attenuation coefficient, as well as an increase in the GB EC, a decrease in the thickness and density of the GB wall and bile, which can prevent further progression of biliary tract damage in patients with SMD. Conclusions. The use of Ursoker is effective and safe in the complex therapy of SMD patients with hepatobiliary system lesions.
- Open Access
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 97-103
Possibilities of split-dose enzyme administration in patients with type 2 diabetes mellitus with secondary exocrine pancreatic insufficiency
Objective — to evaluate the efficacy and safety of split‑dose enzyme administration (Firulin® 10000) compared to a single dose of enzymes in patients with secondary exocrine pancreatic insufficiency (EPI) and type 2 diabetes mellitus (DM‑2) during enzyme replacement therapy (ERT). Materials and methods. A randomized, multicenter, parallel‑group comparative study was conducted to investigate the efficacy and safety of split‑dose enzyme administration (Firulin® 10000) compared to a single dose of enzymes during a meal in the treatment of secondary EPI in patients with DM‑2. The study included 60 patients with DM‑2 and secondary EPI aged 35 — 65 years, of whom 32 were men and 28 were women. In all patients included in the study, the level of fecal pancreatic elastase was within 50 — 150 mg/g (107.2±11.3 mg/g), i.e., it corresponded to the average degree of EPI. All patients were assessed for exocrine pancreatic function using: indirect non‑invasive tests of blood levels of: magnesium, zinc, vitamin D, as well as prealbumin and retinol‑binding protein. Patients were randomized into 2 groups: Group I (n=30) — patients took Firulin® 10000 at a dose of 80,000 units per day for 12 weeks. The enzyme preparation was taken in separate doses of 10,000 units for each meal during meals. Group II (n=30) — patients who took high‑dose enzyme preparations 80,000 per day, the entire dose once during meals for 12 weeks. Results. Before treatment, all examined patients had nonspecific gastroenterological manifestations associated with EPI: diarrhea, abdominal pain (AB), flatulence, weight loss. The main complaint of patients was defecation disorders, which were detected in each patient. Against the background of combined treatment with the use of ERT, the clinical condition of patients in both groups improved. After completion of treatment, abdominal pain was not detected in any patient in either group; normalization of defecation with a decrease in flatulence was noted. In the ERT background, no weight loss was recorded in any patient. In patients with DM‑2 with secondary EPI before treatment, a decrease in vitamin D, retinol‑binding protein, prealbumin was more often noted, the levels of these indicators were significantly lower than in healthy subjects. Against the background of the use of separately dosed intake of enzymes (Firulin® 10000) in patients with DM‑2 with secondary EPI, the levels of vitamin D and retinol‑binding protein were significantly higher than in patients after standard ERT. Conclusions. Comprehensive treatment of DM‑2 with secondary EPI using an adequate dose of enzyme preparations is effective and helps reduce the clinical manifestations of EPI. Against the background of the use of separately dosed intake of enzymes (Firulin® 10000) in patients with DM‑2 with secondary EPI, the levels of vitamin D and retinol‑binding protein were significantly higher than in patients after standard ERT, which may indicate greater efficacy, feasibility and prospects for the use of a separately dosed ERT scheme. Firulin® 10000 is safe and well tolerated by patients; no adverse reactions have been recorded during its use.
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 97-103
Open AccessPossibilities of split-dose enzyme administration in patients with type 2 diabetes mellitus with secondary exocrine pancreatic insufficiency
Objective — to evaluate the efficacy and safety of split‑dose enzyme administration (Firulin® 10000) compared to a single dose of enzymes in patients with secondary exocrine pancreatic insufficiency (EPI) and type 2 diabetes mellitus (DM‑2) during enzyme replacement therapy (ERT). Materials and methods. A randomized, multicenter, parallel‑group comparative study was conducted to investigate the efficacy and safety of split‑dose enzyme administration (Firulin® 10000) compared to a single dose of enzymes during a meal in the treatment of secondary EPI in patients with DM‑2. The study included 60 patients with DM‑2 and secondary EPI aged 35 — 65 years, of whom 32 were men and 28 were women. In all patients included in the study, the level of fecal pancreatic elastase was within 50 — 150 mg/g (107.2±11.3 mg/g), i.e., it corresponded to the average degree of EPI. All patients were assessed for exocrine pancreatic function using: indirect non‑invasive tests of blood levels of: magnesium, zinc, vitamin D, as well as prealbumin and retinol‑binding protein. Patients were randomized into 2 groups: Group I (n=30) — patients took Firulin® 10000 at a dose of 80,000 units per day for 12 weeks. The enzyme preparation was taken in separate doses of 10,000 units for each meal during meals. Group II (n=30) — patients who took high‑dose enzyme preparations 80,000 per day, the entire dose once during meals for 12 weeks. Results. Before treatment, all examined patients had nonspecific gastroenterological manifestations associated with EPI: diarrhea, abdominal pain (AB), flatulence, weight loss. The main complaint of patients was defecation disorders, which were detected in each patient. Against the background of combined treatment with the use of ERT, the clinical condition of patients in both groups improved. After completion of treatment, abdominal pain was not detected in any patient in either group; normalization of defecation with a decrease in flatulence was noted. In the ERT background, no weight loss was recorded in any patient. In patients with DM‑2 with secondary EPI before treatment, a decrease in vitamin D, retinol‑binding protein, prealbumin was more often noted, the levels of these indicators were significantly lower than in healthy subjects. Against the background of the use of separately dosed intake of enzymes (Firulin® 10000) in patients with DM‑2 with secondary EPI, the levels of vitamin D and retinol‑binding protein were significantly higher than in patients after standard ERT. Conclusions. Comprehensive treatment of DM‑2 with secondary EPI using an adequate dose of enzyme preparations is effective and helps reduce the clinical manifestations of EPI. Against the background of the use of separately dosed intake of enzymes (Firulin® 10000) in patients with DM‑2 with secondary EPI, the levels of vitamin D and retinol‑binding protein were significantly higher than in patients after standard ERT, which may indicate greater efficacy, feasibility and prospects for the use of a separately dosed ERT scheme. Firulin® 10000 is safe and well tolerated by patients; no adverse reactions have been recorded during its use.
- Open Access
- 23 December 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 4,p. 27-35
Features of diverticular disease in patients with metabolic disorders
Objective — to identify the clinical features of uncomplicated diverticular disease (UDD) in the context of metabolic disorders (MD); to analyze the main representatives of the obligate and mucin-producing intestinal flora; and to evaluate endoscopic and morphological changes in the colonic mucosa in patients with isolated UDD and those with concomitant MD. Materials and methods. The study included 259 patients with UDD (101 men and 158 women; mean age 65.6±1.45 years). All participants underwent body mass index (BMI) assessment and total colonoscopy with evaluation of diverticular inflammation activity. In 172 patients, microbiome profiling was performed by qRT-PCR using 16S rRNA gene-specific primers. During colonoscopy, mucosal biopsies were taken from diverticular orifices for PAS staining, immunohistochemical analysis, and morphometric assessment of the functional state of the colonic mucosa. Results. Patients with UDD and concomitant MD demonstrated a significantly higher rate of recurrent diverticular inflammation—52 (24.1%) vs 3 (6.9%) (p=0.013). Symptomatic uncomplicated diverticular disease (SUDD) was more frequently diagnosed in patients with metabolic disorders—121 (56.0%) vs 13 (30.2%) (p=0.002). Microbiome analysis revealed a tendency toward decreased levels of the main representatives of the obligate flora and of butyrate-producing bacterial strains. The mean score of endoscopic activity of diverticular inflammation in patients with MD was higher than in the group with normal BMI and correlated with a higher intensity of inflammation according to morphological and morphometric analysis. Conclusions. Patients with metabolic disorders exhibit a significantly higher frequency of recurrent diverticular inflammation. This may be attributed to more intense mucosal inflammation and altered mucus production resulting from a marked reduction in butyrate-producing microbiota and the predominance of Bacteroidetes species.
- 23 December 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 4,p. 27-35
Open AccessFeatures of diverticular disease in patients with metabolic disorders
Objective — to identify the clinical features of uncomplicated diverticular disease (UDD) in the context of metabolic disorders (MD); to analyze the main representatives of the obligate and mucin-producing intestinal flora; and to evaluate endoscopic and morphological changes in the colonic mucosa in patients with isolated UDD and those with concomitant MD. Materials and methods. The study included 259 patients with UDD (101 men and 158 women; mean age 65.6±1.45 years). All participants underwent body mass index (BMI) assessment and total colonoscopy with evaluation of diverticular inflammation activity. In 172 patients, microbiome profiling was performed by qRT-PCR using 16S rRNA gene-specific primers. During colonoscopy, mucosal biopsies were taken from diverticular orifices for PAS staining, immunohistochemical analysis, and morphometric assessment of the functional state of the colonic mucosa. Results. Patients with UDD and concomitant MD demonstrated a significantly higher rate of recurrent diverticular inflammation—52 (24.1%) vs 3 (6.9%) (p=0.013). Symptomatic uncomplicated diverticular disease (SUDD) was more frequently diagnosed in patients with metabolic disorders—121 (56.0%) vs 13 (30.2%) (p=0.002). Microbiome analysis revealed a tendency toward decreased levels of the main representatives of the obligate flora and of butyrate-producing bacterial strains. The mean score of endoscopic activity of diverticular inflammation in patients with MD was higher than in the group with normal BMI and correlated with a higher intensity of inflammation according to morphological and morphometric analysis. Conclusions. Patients with metabolic disorders exhibit a significantly higher frequency of recurrent diverticular inflammation. This may be attributed to more intense mucosal inflammation and altered mucus production resulting from a marked reduction in butyrate-producing microbiota and the predominance of Bacteroidetes species.
- Open Access
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 3,p. 22-30
Possibilities of multi-ingredient therapy in the management of patients with metabolic dysfunction-associated steatоtic liver disease and type 2 diabetes mellitus
Objective — to evaluate the efficacy and safety of multi‑ingredient complex therapy in patients with metabolic dysfunction‑associated steatоtic liver disease (MASLD) with type 2 diabetes mellitus (DM‑2) using S‑adenosylmethionine with glutathione. Materials and methods. We conducted a multicenter randomized prospective comparative study in parallel groups to investigate the efficacy and safety of the drug Hepavista Detox, containing 400 mg of S‑adenosylmethionine and 250 mg of glutathione. 91 patients (51 men and 40 women) aged 39 to 75 years were observed. They were divided into two groups: the main group, comprising 61 patients (35 men and 26 women) with a combination of MASLD and DM‑2, and the comparison group including 30 patients (16 men and 14 women) with DM2 without MASLD. The control group consisted of 30 practically healthy volunteers (16 men and 14 women aged 28—59 years) who had no complaints from the gastrointestinal tract, in whom MASLD and DM‑2 were excluded during a comprehensive examination. All patients underwent a comprehensive clinical, biochemical and ultrasound examination, anthropometric examination with calculation of body mass index (BMI) and HOMA‑IR index (Homeostatic Model Assessment). The diagnosis of MASLD was made based on the presence of DM‑2 and sonographic signs of steatosis and the degree of its severity (with steatometry), biochemical signs of steatohepatitis (increased activity of liver enzymes). Results. MASLD, along with overweight and obesity, is often found in patients with DM‑2 and may be one of the predictors of a decompensated course of DM‑2. Steatohepatitis was detected in 41.0% of MASLD patients with DM‑2, and steatosis in — 59.0%. In the presence of MASLD in patients with DM‑2, not only cytolysis markers increase, but also lipid and carbohydrate metabolism indicators significantly worsen, which allows us to consider MASLD as a factor in the progression of DM‑2. All MASLD patients with DM‑2 were diagnosed with steatosis before treatment, and 57.4% had liver fibrosis. Conclusions. The use of multi‑ingredient therapy with “Hepavista detox” in patients with MASLD and DM‑2 is pathogenetically directed, effective, and safe. After a three‑month course of Hepavista detox, patients had normalized the levels of liver enzymes (alanine aminotransferases, aspartate aminotransferases, glutamyl transpeptidases), a tendency to reduce insulin resistance with a decrease in the HOMA‑IR index, stabilization of lipid metabolism with an increase in high‑density lipoprotein cholesterol, a decrease in the ultrasound attenuation coefficient and a decrease in the intensity of liver steatosis. This allows us to recommend Hepavista detox for the treatment of patients with MASLD with type 2 diabetes mellitus.
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 3,p. 22-30
Open AccessPossibilities of multi-ingredient therapy in the management of patients with metabolic dysfunction-associated steatоtic liver disease and type 2 diabetes mellitus
Objective — to evaluate the efficacy and safety of multi‑ingredient complex therapy in patients with metabolic dysfunction‑associated steatоtic liver disease (MASLD) with type 2 diabetes mellitus (DM‑2) using S‑adenosylmethionine with glutathione. Materials and methods. We conducted a multicenter randomized prospective comparative study in parallel groups to investigate the efficacy and safety of the drug Hepavista Detox, containing 400 mg of S‑adenosylmethionine and 250 mg of glutathione. 91 patients (51 men and 40 women) aged 39 to 75 years were observed. They were divided into two groups: the main group, comprising 61 patients (35 men and 26 women) with a combination of MASLD and DM‑2, and the comparison group including 30 patients (16 men and 14 women) with DM2 without MASLD. The control group consisted of 30 practically healthy volunteers (16 men and 14 women aged 28—59 years) who had no complaints from the gastrointestinal tract, in whom MASLD and DM‑2 were excluded during a comprehensive examination. All patients underwent a comprehensive clinical, biochemical and ultrasound examination, anthropometric examination with calculation of body mass index (BMI) and HOMA‑IR index (Homeostatic Model Assessment). The diagnosis of MASLD was made based on the presence of DM‑2 and sonographic signs of steatosis and the degree of its severity (with steatometry), biochemical signs of steatohepatitis (increased activity of liver enzymes). Results. MASLD, along with overweight and obesity, is often found in patients with DM‑2 and may be one of the predictors of a decompensated course of DM‑2. Steatohepatitis was detected in 41.0% of MASLD patients with DM‑2, and steatosis in — 59.0%. In the presence of MASLD in patients with DM‑2, not only cytolysis markers increase, but also lipid and carbohydrate metabolism indicators significantly worsen, which allows us to consider MASLD as a factor in the progression of DM‑2. All MASLD patients with DM‑2 were diagnosed with steatosis before treatment, and 57.4% had liver fibrosis. Conclusions. The use of multi‑ingredient therapy with “Hepavista detox” in patients with MASLD and DM‑2 is pathogenetically directed, effective, and safe. After a three‑month course of Hepavista detox, patients had normalized the levels of liver enzymes (alanine aminotransferases, aspartate aminotransferases, glutamyl transpeptidases), a tendency to reduce insulin resistance with a decrease in the HOMA‑IR index, stabilization of lipid metabolism with an increase in high‑density lipoprotein cholesterol, a decrease in the ultrasound attenuation coefficient and a decrease in the intensity of liver steatosis. This allows us to recommend Hepavista detox for the treatment of patients with MASLD with type 2 diabetes mellitus.
- Open Access
- 26 September 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 3,p. 97-103
Probiotics in the complex of Helicopter pylori eradication therapy: effectiveness, possibilities of complications prevention
Objective — to assess the efficacy and safety of complex eradication therapy of Helicobacter рylori using Saccharomyces boulardii (Esbulardi), with an assessment of the impact of treatment on the intestinal microbiome and the role of probiotics in the dysbiosis prevention. Materials and methods. We conducted a multicenter, prospective, randomized, controlled, comparative study in parallel groups. Under our observation were 78 patients with chronic gastritis associated with H. pylori infection, with the presence of erosions of the gastric mucosa, who had no previous episodes of eradication of helicobacter infection. Among the examined were 40 men and 38 women aged 26 to 53 years, and 30 practically healthy individuals of the same age who were the control group. To analyze the presence of Helicobacter pylori, all patients underwent a 13Сurease breath test. In addition, all patients before and after therapy were assessed for changes in the intestinal microbiome according to the hydrogen breath test to analyze the presence of bacterial overgrowth syndrome (SIBO). Before inclusion in the study, all patients underwent fibrogastroduodenoscopy. During endoscopy, a gastric mucosal biopsy (GM) was performed to confirm the diagnosis of chronic gastritis. Of the 78 screened patients, 62 patients were randomized and divided into 2 groups. 30 patients received quadruple therapy for the eradication of H. pylori, which included amoxicillin, clarithromycin for 14 days, PPIs and bismuth preparations, in a dosage that meets the Maastricht VI recommendations. In addition, patients received the probiotic Esbulardi (Saccharomyces boulardii) from the company Bichels (Ukraine). 32 patients received only standard eradication therapy and were the comparison group. Results. Before treatment, the clinical, endoscopic and morphological picture of chronic gastritis (CG) in patients of both groups did not differ. In patients with H. pylori‑associated CG with erosions of the gastric mucosa, complaints of epigastric pain and manifestations of organic dyspepsia dominated before treatment, which characterized postprandial distress syndrome in the presence of single erosions in the antrum of the stomach with an increase in proinflammatory cells in the gastric mucosa, glandular atrophy and focal metaplasia. The use of Esbulardi in the complex of H. pylori eradication therapy allowed for improved tolerability of the treatment course and its increased effectiveness. While in the group of patients who took Esbulardi, all patients completed the treatment, in the comparison group, only 28 (87.5%) patients completed the therapeutic course. The effectiveness of treatment in the main group of patients was 86.7%, in the comparison group — 78.2% (p<0.05). The use of Esbulardi significantly affected the symptoms of organic dyspepsia in patients with H. pylori‑associated CG, the minimization of which significantly affects the tolerability of the eradication course and improves the clinical picture of the disease. In the group of patients who took Esbulardi, the frequency of SIBO significantly decreased compared to patients before treatment (30.0% and 58.0%, respectively, p<0.05). At the same time, among patients receiving standard eradication therapy, the frequency of SIBO increased and exceeded the indicators not only of the main group, but also of patients before therapy (59.4%). Conclusions. The use of Esbulardi in the complex therapy of patients with H. pylori‑associated CG with the presence of erosions of the GM was effective and safe, improved the tolerability of treatment and increased the level of eradication of infection. The use of Esbulardi reduced the frequency and intensity of SIBO, which prevented the development of intestinal lesions.
- 26 September 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 3,p. 97-103
Open AccessProbiotics in the complex of Helicopter pylori eradication therapy: effectiveness, possibilities of complications prevention
Objective — to assess the efficacy and safety of complex eradication therapy of Helicobacter рylori using Saccharomyces boulardii (Esbulardi), with an assessment of the impact of treatment on the intestinal microbiome and the role of probiotics in the dysbiosis prevention. Materials and methods. We conducted a multicenter, prospective, randomized, controlled, comparative study in parallel groups. Under our observation were 78 patients with chronic gastritis associated with H. pylori infection, with the presence of erosions of the gastric mucosa, who had no previous episodes of eradication of helicobacter infection. Among the examined were 40 men and 38 women aged 26 to 53 years, and 30 practically healthy individuals of the same age who were the control group. To analyze the presence of Helicobacter pylori, all patients underwent a 13Сurease breath test. In addition, all patients before and after therapy were assessed for changes in the intestinal microbiome according to the hydrogen breath test to analyze the presence of bacterial overgrowth syndrome (SIBO). Before inclusion in the study, all patients underwent fibrogastroduodenoscopy. During endoscopy, a gastric mucosal biopsy (GM) was performed to confirm the diagnosis of chronic gastritis. Of the 78 screened patients, 62 patients were randomized and divided into 2 groups. 30 patients received quadruple therapy for the eradication of H. pylori, which included amoxicillin, clarithromycin for 14 days, PPIs and bismuth preparations, in a dosage that meets the Maastricht VI recommendations. In addition, patients received the probiotic Esbulardi (Saccharomyces boulardii) from the company Bichels (Ukraine). 32 patients received only standard eradication therapy and were the comparison group. Results. Before treatment, the clinical, endoscopic and morphological picture of chronic gastritis (CG) in patients of both groups did not differ. In patients with H. pylori‑associated CG with erosions of the gastric mucosa, complaints of epigastric pain and manifestations of organic dyspepsia dominated before treatment, which characterized postprandial distress syndrome in the presence of single erosions in the antrum of the stomach with an increase in proinflammatory cells in the gastric mucosa, glandular atrophy and focal metaplasia. The use of Esbulardi in the complex of H. pylori eradication therapy allowed for improved tolerability of the treatment course and its increased effectiveness. While in the group of patients who took Esbulardi, all patients completed the treatment, in the comparison group, only 28 (87.5%) patients completed the therapeutic course. The effectiveness of treatment in the main group of patients was 86.7%, in the comparison group — 78.2% (p<0.05). The use of Esbulardi significantly affected the symptoms of organic dyspepsia in patients with H. pylori‑associated CG, the minimization of which significantly affects the tolerability of the eradication course and improves the clinical picture of the disease. In the group of patients who took Esbulardi, the frequency of SIBO significantly decreased compared to patients before treatment (30.0% and 58.0%, respectively, p<0.05). At the same time, among patients receiving standard eradication therapy, the frequency of SIBO increased and exceeded the indicators not only of the main group, but also of patients before therapy (59.4%). Conclusions. The use of Esbulardi in the complex therapy of patients with H. pylori‑associated CG with the presence of erosions of the GM was effective and safe, improved the tolerability of treatment and increased the level of eradication of infection. The use of Esbulardi reduced the frequency and intensity of SIBO, which prevented the development of intestinal lesions.
- Open Access
- 19 June 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 62-82
Modern possibilities of treatment and prophylaxis of NSAID-induced gastric and intestinal disorders
Objective — to evaluate the clinical, endoscopic, microbiological and morphological efficacy and safety of rebamipide in the prevention of gastro‑ and enterocolopathy in patients with osteoarthritis taking non‑steroidal anti‑inflammatory drugs (NSAIDs). Materials and methods. A multicenter, randomized, comparative study in parallel groups was conducted to investigate the efficacy and safety of rebamipide (Mukogen) in the prevention of NSAID‑induced gastro‑ and enterocolopathy in patients with deformative osteoarthritis taking NSAIDs. We observed 123 patients with osteoarthritis (OA) aged 42 to 67 years (mean age 56.2±4.3 years). Among them, 55 were women and 68 were men. The diagnosis of OA was made at least 12 months before inclusion in the study. All patients had generalized OA with involvement of more than 3 large joints, among which at least 1 joint had radiological stage III OA. Patients received chondroprotectors as basic therapy for the underlying disease. In addition, patients used disease‑modifying osteoarthritis drugs — NSAIDs. Over the past 6 months before inclusion in the study, patients took non‑selective NSAIDs on average at least 1—2 times a week, and in case of exacerbation of OA with joint pain at least 1 time per day. The examined patients underwent a non‑invasive hydrogen breath test before and after therapy to analyze the presence of bacterial overgrowth syndrome. In addition, the patients underwent fibrogastroduodenoscopy and colonoscopy, during one visit with the use of propofol for sedation and anesthesia. During endoscopy, a biopsy of the mucosa of the stomach and large intestine was performed. After the examination, only 100 OA patients were included in the study. OA patients were randomly divided into 2 groups: Group I (50 patients) — OA patients receiving basic therapy and rebamipide (Mukogen) 300 mg per day for 12 weeks. Group II (50 patients) — OA patients receiving basic therapy and proton pump inhibitor 20 mg per day for 12 weeks. Results. Patients with a high and medium risk of NSAID‑induced gastropathy and enterocolopathy predominated in the group of patients with OA, which requires additional stratification before prescribing NSAIDs. Clinical manifestations of gastropathy are detected in a third, and enterocolopathy in half of patients taking NSAIDs, the clinical picture is nonspecific and the symptoms have low intensity. Endoscopic changes in the gastric and intestinal mucosa in patients with NSAID‑gastro‑enterocolopathy are more common than its clinical manifestations. The presence of endoscopic changes correlates with the degree of risk. Morphological changes in the gastric and intestinal mucosa are detected in almost all patients taking NSAIDs and are characterized by the presence of damage to the surface epithelium and hemorrhages with stromal edema with inflammatory cell infiltration and gland atrophy, which correlates with the degree of risk of NSAID‑induced gastrointestinal lesions. This is combined with disturbances in the quantitative and qualitative composition of mucus and increased permeability of the epithelial mucosal barrier of the stomach and intestines. Disturbances of the mucosal barriers of the gastrointestinal tract with increased epithelial permeability and bacterial overgrowth syndrome can be considered as additional pathogenetic mechanisms of the development of NSAID‑induced gastro‑ and enterocolopathy. Conclusions. Evaluation of the appointment of Mucogen with analysis of clinical and endoscopic, morphological efficacy, effect on the gastrointestinal mucosal barrier with modification, epithelial permeability, mucus formation and bacterial overgrowth syndrome proved its greater effectiveness compared to proton pump inhibitors for the complex prevention and treatment of NSAID‑induced gastro‑ and enterocolopathy in patients with osteoarthritis.
- 19 June 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 62-82
Open AccessModern possibilities of treatment and prophylaxis of NSAID-induced gastric and intestinal disorders
Objective — to evaluate the clinical, endoscopic, microbiological and morphological efficacy and safety of rebamipide in the prevention of gastro‑ and enterocolopathy in patients with osteoarthritis taking non‑steroidal anti‑inflammatory drugs (NSAIDs). Materials and methods. A multicenter, randomized, comparative study in parallel groups was conducted to investigate the efficacy and safety of rebamipide (Mukogen) in the prevention of NSAID‑induced gastro‑ and enterocolopathy in patients with deformative osteoarthritis taking NSAIDs. We observed 123 patients with osteoarthritis (OA) aged 42 to 67 years (mean age 56.2±4.3 years). Among them, 55 were women and 68 were men. The diagnosis of OA was made at least 12 months before inclusion in the study. All patients had generalized OA with involvement of more than 3 large joints, among which at least 1 joint had radiological stage III OA. Patients received chondroprotectors as basic therapy for the underlying disease. In addition, patients used disease‑modifying osteoarthritis drugs — NSAIDs. Over the past 6 months before inclusion in the study, patients took non‑selective NSAIDs on average at least 1—2 times a week, and in case of exacerbation of OA with joint pain at least 1 time per day. The examined patients underwent a non‑invasive hydrogen breath test before and after therapy to analyze the presence of bacterial overgrowth syndrome. In addition, the patients underwent fibrogastroduodenoscopy and colonoscopy, during one visit with the use of propofol for sedation and anesthesia. During endoscopy, a biopsy of the mucosa of the stomach and large intestine was performed. After the examination, only 100 OA patients were included in the study. OA patients were randomly divided into 2 groups: Group I (50 patients) — OA patients receiving basic therapy and rebamipide (Mukogen) 300 mg per day for 12 weeks. Group II (50 patients) — OA patients receiving basic therapy and proton pump inhibitor 20 mg per day for 12 weeks. Results. Patients with a high and medium risk of NSAID‑induced gastropathy and enterocolopathy predominated in the group of patients with OA, which requires additional stratification before prescribing NSAIDs. Clinical manifestations of gastropathy are detected in a third, and enterocolopathy in half of patients taking NSAIDs, the clinical picture is nonspecific and the symptoms have low intensity. Endoscopic changes in the gastric and intestinal mucosa in patients with NSAID‑gastro‑enterocolopathy are more common than its clinical manifestations. The presence of endoscopic changes correlates with the degree of risk. Morphological changes in the gastric and intestinal mucosa are detected in almost all patients taking NSAIDs and are characterized by the presence of damage to the surface epithelium and hemorrhages with stromal edema with inflammatory cell infiltration and gland atrophy, which correlates with the degree of risk of NSAID‑induced gastrointestinal lesions. This is combined with disturbances in the quantitative and qualitative composition of mucus and increased permeability of the epithelial mucosal barrier of the stomach and intestines. Disturbances of the mucosal barriers of the gastrointestinal tract with increased epithelial permeability and bacterial overgrowth syndrome can be considered as additional pathogenetic mechanisms of the development of NSAID‑induced gastro‑ and enterocolopathy. Conclusions. Evaluation of the appointment of Mucogen with analysis of clinical and endoscopic, morphological efficacy, effect on the gastrointestinal mucosal barrier with modification, epithelial permeability, mucus formation and bacterial overgrowth syndrome proved its greater effectiveness compared to proton pump inhibitors for the complex prevention and treatment of NSAID‑induced gastro‑ and enterocolopathy in patients with osteoarthritis.
- Open Access
- 6 June 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 75-84
Current concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN. Review
Recent decades have been marked by several important milestones in the field of gastritis. New epidemiological reports were received, especially from countries with a high incidence of gastric cancer, and H. pylori infection was recognized as the most important cause of gastritis, due to which it was quickly included among the primary infectious oncogenic agents. Clinical strategies for the detection and eradication of H. pylori infection were developed, the previously unsuspected clinical and pathological significance of the gastric microbiota was established, and extraordinary progress was made in the technology of esophagogastroduodenoscopy. Histological determination of gastritis from the point of view of «stage» (that is, risk stratification of stomach cancer) has entered clinical practice. In addition to the Sydney and Houston gastritis classifications, six editions of the Maastricht Consensus (1996—2022) and the Kyoto Global Consensus deserve special attention, thanks to which agreements were reached in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H. pylori gastritis, which accounts for more than 90% of all forms of gastritis worldwide. The Real‑world Gastritis Initiative (RE.GA.IN) marks the next step in the ongoing quest to achieve a better understanding of various gastric conditions. The RE.GA.IN consensus was concluded in Venice in November 2022 after 8 months of intensive global scientific reasoning. RE.GA.IN’s mission itself has been focused on critically reviewing, updating, sharing and building consensus on the current scientific knowledge of inflammatory gastric lesions. It includes eight sections on clinicopathological topics, each consisting of preamble, which briefly presents the following statements and corresponding explanatory texts. For each statement, the level of evidence (assessed according to a predefined four‑level scale) and the strength of recommendations according to the GRADE system are reported. The following topics were considered in the consensus: 1) definition and problem of classification of gastritis; 2) spectrum of H. pylori gastritis; 3) key diagnosis of H. pylori gastritis; 4) H. pylori gastritis: clinical results; 5) autoimmune gastritis; 6) gastritis of low prevalence; 7) gastritis and gastric microbiota; 8) epidemiology of gastritis and associated precancerous and neoplastic lesions. Thus, the most controversial aspects of gastritis were addressed and a comprehensive and diverse body of knowledge was brought together to use patient‑oriented evidence to assist physicians in their clinical practice.
- 6 June 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 75-84
Open AccessCurrent concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN. Review
Recent decades have been marked by several important milestones in the field of gastritis. New epidemiological reports were received, especially from countries with a high incidence of gastric cancer, and H. pylori infection was recognized as the most important cause of gastritis, due to which it was quickly included among the primary infectious oncogenic agents. Clinical strategies for the detection and eradication of H. pylori infection were developed, the previously unsuspected clinical and pathological significance of the gastric microbiota was established, and extraordinary progress was made in the technology of esophagogastroduodenoscopy. Histological determination of gastritis from the point of view of «stage» (that is, risk stratification of stomach cancer) has entered clinical practice. In addition to the Sydney and Houston gastritis classifications, six editions of the Maastricht Consensus (1996—2022) and the Kyoto Global Consensus deserve special attention, thanks to which agreements were reached in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H. pylori gastritis, which accounts for more than 90% of all forms of gastritis worldwide. The Real‑world Gastritis Initiative (RE.GA.IN) marks the next step in the ongoing quest to achieve a better understanding of various gastric conditions. The RE.GA.IN consensus was concluded in Venice in November 2022 after 8 months of intensive global scientific reasoning. RE.GA.IN’s mission itself has been focused on critically reviewing, updating, sharing and building consensus on the current scientific knowledge of inflammatory gastric lesions. It includes eight sections on clinicopathological topics, each consisting of preamble, which briefly presents the following statements and corresponding explanatory texts. For each statement, the level of evidence (assessed according to a predefined four‑level scale) and the strength of recommendations according to the GRADE system are reported. The following topics were considered in the consensus: 1) definition and problem of classification of gastritis; 2) spectrum of H. pylori gastritis; 3) key diagnosis of H. pylori gastritis; 4) H. pylori gastritis: clinical results; 5) autoimmune gastritis; 6) gastritis of low prevalence; 7) gastritis and gastric microbiota; 8) epidemiology of gastritis and associated precancerous and neoplastic lesions. Thus, the most controversial aspects of gastritis were addressed and a comprehensive and diverse body of knowledge was brought together to use patient‑oriented evidence to assist physicians in their clinical practice.
- Open Access
- 26 March 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 59-70
Efficacy and safety of prokinetics in gastrointestinal disorders. Review
Prokinetics are a heterogeneous class of drugs that enhance and coordinate gastrointestinal (GI) smooth muscle contraction to enhance gastric emptying and improve a wide range of motility disorders and related symptoms, even though high‑quality evidence is limited. These disorders range from very common but non‑fatal disorders such as functional dyspepsia (FD), gastroparesis or chronic idiopathic constipation (CIS) to severe motility disorders including chronic intestinal pseudo‑obstruction. Different classes of prokinetic agents with different mechanisms are available worldwide. Because of the great clinical need, many new drugs are currently under investigation or have recently been brought to market. Based on the latest recommendations of the European Association of Neurogastroenterology and Motility and the American Society of Neurogastroenterology and Motility, a review of the efficacy and safety of prokinetic agents in gastrointestinal disorders is presented. Such classes of kinetic agents as cholinesterase inhibitors (pyridostigmine, neostigmine, acotiamide), motilin agonists (erythromycin, mitemcinal), ghrelin agonists (relamorelin), muscarinic receptor agonists (bethanechol), 5‑HT4 receptor agonists (prucalopride, tegaserod, mosapride), dopamine D2 receptor antagonists (metoclopramide, domperidone, itopride, levosulpiride) were considered. The presented results demonstrated the potential benefits of prokinetics in improving gastrointestinal motility and symptom control through appropriate dose adjustments. However, further studies are needed to examine specific patient populations, optimal dosing regimens, and long‑term safety profiles of these drugs.
- 26 March 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 59-70
Open AccessEfficacy and safety of prokinetics in gastrointestinal disorders. Review
Prokinetics are a heterogeneous class of drugs that enhance and coordinate gastrointestinal (GI) smooth muscle contraction to enhance gastric emptying and improve a wide range of motility disorders and related symptoms, even though high‑quality evidence is limited. These disorders range from very common but non‑fatal disorders such as functional dyspepsia (FD), gastroparesis or chronic idiopathic constipation (CIS) to severe motility disorders including chronic intestinal pseudo‑obstruction. Different classes of prokinetic agents with different mechanisms are available worldwide. Because of the great clinical need, many new drugs are currently under investigation or have recently been brought to market. Based on the latest recommendations of the European Association of Neurogastroenterology and Motility and the American Society of Neurogastroenterology and Motility, a review of the efficacy and safety of prokinetic agents in gastrointestinal disorders is presented. Such classes of kinetic agents as cholinesterase inhibitors (pyridostigmine, neostigmine, acotiamide), motilin agonists (erythromycin, mitemcinal), ghrelin agonists (relamorelin), muscarinic receptor agonists (bethanechol), 5‑HT4 receptor agonists (prucalopride, tegaserod, mosapride), dopamine D2 receptor antagonists (metoclopramide, domperidone, itopride, levosulpiride) were considered. The presented results demonstrated the potential benefits of prokinetics in improving gastrointestinal motility and symptom control through appropriate dose adjustments. However, further studies are needed to examine specific patient populations, optimal dosing regimens, and long‑term safety profiles of these drugs.
- Open Access
- 21 December 2024
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 58 (4) , 286-294
Current concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN
Recent decades have been marked by several important milestones in the field of gastritis. New epidemiological reports were received, especially from countries with a high incidence of gastric cancer, and H.pylori infection was recognized as the most important cause of gastritis, due to which it was quickly included in the primary infectious oncogenic agents. Clinical strategies for the detection and eradication of H.pylori infection were developed, the previously unsuspected clinical and pathological significance of gastric microbiota was established, and extraordinary progress was made in the technology of esophagogastroduodenoscopy. Histological determination of gastritis in terms of stage (that is, risk stratification of stomach cancer) was implemented into clinical practice. In addition to the Sydney and Houston gastritis classifications, the six editions of the Maastricht Consensus (1996–2022) and the Kyoto Global Consensus deserve special attention, thanks to which broad agreements and significant scientific achievements became possible in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H.pylori gastritis, which accounts for more than 90 % of all forms of gastritis worldwide. The Real-world Gastritis Initiative (RE.GA.IN) marks the next step in the ongoing search to achieve a better understanding of various gastric conditions. The RE.GA.IN consensus was concluded in Venice in November 2022 after 8 months of intensive global scientific reasonings. RE.GA.IN mission itself has been focused on critically reviewing, updating, sharing and building consensus on the current scientific knowledge of inflammatory gastric lesions. It includes eight sections on clinicopathological topics, each consisting of preamble, which presents brief statements and corresponding explanatory texts. For each statement, the level of evidence (assessed according to a predefined four-level scale) and the strength of recommendations on the GRADE system are reported. The following topics were considered in the consensus: 1) definition and classification issues of gastritis; 2) spectrum of H.pylori gastritis; 3) key diagnosis of H.pylori gastritis; 4) H.pylori gastritis: clinical results; 5) autoimmune gastritis; 6) gastritis of low prevalence; 7) gastritis and gastric microbiota; 8) epidemiology of gastritis and associated precancerous and neoplastic lesions. Thus, the most controversial aspects of gastritis were addressed, a comprehensive and diverse body of knowledge was brought together to use patient-oriented evidence to assist physicians in their real-world clinical practice.
- 21 December 2024
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 58 (4) , 286-294
Open AccessCurrent concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN
Recent decades have been marked by several important milestones in the field of gastritis. New epidemiological reports were received, especially from countries with a high incidence of gastric cancer, and H.pylori infection was recognized as the most important cause of gastritis, due to which it was quickly included in the primary infectious oncogenic agents. Clinical strategies for the detection and eradication of H.pylori infection were developed, the previously unsuspected clinical and pathological significance of gastric microbiota was established, and extraordinary progress was made in the technology of esophagogastroduodenoscopy. Histological determination of gastritis in terms of stage (that is, risk stratification of stomach cancer) was implemented into clinical practice. In addition to the Sydney and Houston gastritis classifications, the six editions of the Maastricht Consensus (1996–2022) and the Kyoto Global Consensus deserve special attention, thanks to which broad agreements and significant scientific achievements became possible in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H.pylori gastritis, which accounts for more than 90 % of all forms of gastritis worldwide. The Real-world Gastritis Initiative (RE.GA.IN) marks the next step in the ongoing search to achieve a better understanding of various gastric conditions. The RE.GA.IN consensus was concluded in Venice in November 2022 after 8 months of intensive global scientific reasonings. RE.GA.IN mission itself has been focused on critically reviewing, updating, sharing and building consensus on the current scientific knowledge of inflammatory gastric lesions. It includes eight sections on clinicopathological topics, each consisting of preamble, which presents brief statements and corresponding explanatory texts. For each statement, the level of evidence (assessed according to a predefined four-level scale) and the strength of recommendations on the GRADE system are reported. The following topics were considered in the consensus: 1) definition and classification issues of gastritis; 2) spectrum of H.pylori gastritis; 3) key diagnosis of H.pylori gastritis; 4) H.pylori gastritis: clinical results; 5) autoimmune gastritis; 6) gastritis of low prevalence; 7) gastritis and gastric microbiota; 8) epidemiology of gastritis and associated precancerous and neoplastic lesions. Thus, the most controversial aspects of gastritis were addressed, a comprehensive and diverse body of knowledge was brought together to use patient-oriented evidence to assist physicians in their real-world clinical practice.